Tsopelas Chris
RAH Radiopharmacy, Nuclear Medicine Department, Royal Adelaide Hospital, Adelaide, SA 5000, Australia.
ScientificWorldJournal. 2015;2015:676719. doi: 10.1155/2015/676719. Epub 2015 Feb 8.
Over the last forty years, a small group of commercial radiopharmaceuticals have found their way into routine medical use, for the diagnostic imaging of patients with infection or inflammation. These molecular radiotracers usually participate in the immune response to an antigen, by tagging leukocytes or other molecules/cells that are endogenous to the process. Currently there is an advancing effort by researchers in the preclinical domain to design and develop new agents for this application. This review discusses radiopharmaceuticals used in the nuclear medicine clinic today, as well as those potential radiotracers that exploit an organism's defence mechanisms to an infectious or inflammatory event.
在过去的四十年里,一小部分商业放射性药物已进入常规医学应用,用于感染或炎症患者的诊断成像。这些分子放射性示踪剂通常通过标记白细胞或该过程中内源性的其他分子/细胞来参与对抗抗原的免疫反应。目前,临床前领域的研究人员正在积极努力设计和开发用于此应用的新型药物。本文综述了当今核医学临床中使用的放射性药物,以及那些利用机体对感染或炎症事件防御机制的潜在放射性示踪剂。